Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the symbol HARP. Citi and SVB Leerink acted as lead managers on the deal.
